Lowey Dannenberg, PC and The Dugan Law Firm, APLC Announce Court Certification of Class Action Involving Payment or Reimbursement of Third Party Payers for All or Part of the Purchase Price of Generic Nexium (Esomeprazole Magnesium), brand or generic Diovan (valsartan), or Brand or Generic Valcyte (valganciclovir hydrochloride)

0

NEW YORK, November 5, 2021 / PRNewswire / –

If you have paid or refunded part or all of the purchase price of generic Nexium (esomeprazole magnesium), brand or generic Diovan (valsartan), or brand or generic Valcyte (valganciclovir hydrochloride), a class action lawsuit may affect your rights.

Your rights may be affected by a class action lawsuit relating to the price paid for the generic Nexium, the brand and generic Diovan, and the brand and generic Valcyte by third party payers (“TPP”) filed against the defendants Sun Pharmaceutical Industries, Ltd. . and Ranbaxy, Inc. The name of the case is In Re Ranbaxy Generic Drug Application Antitrust Litigation, MDL No. 2878, Master File No. 19-md-02878 (D. Mass.). The trial, which is pending in the district of Massachusetts, alleges that the defendants engaged in a scheme in violation of state antitrust, state consumer protection and federal racketeering laws by making false statements to the FDA in connection with the prosecution of interim approvals for new abbreviated drug applications, thus delaying the market launch of generic versions of Nexium, Diovan, and Valcyte. As a result, the lawsuit alleges that the TPP paid or reimbursed for the drugs in issue at higher prices than they would otherwise have been, and the plaintiffs seek to recover damages from the defendants.

This is only a summary. The court did not decide whether the defendants did anything wrong. There is no money available now, and no guarantee that there will be. For more details, please read the Detailed Notice available at www.RanbaxyTPPLitigation.com.

Who is included?

You are a member of the Group (s) if you are a PPT and have purchased or reimbursed prescription drugs as follows:

(1)

National generic Nexium class. From May 27, 2014 to February 1, 2019, you purchased or paid part or all of the purchase price of the generic AB versions of Nexium in the United States and its territories;

(2)

Generic Nexium State Law Class. From May 27, 2014 to February 1, 2019, you purchased or paid part or all of the purchase price of the generic AB versions of Nexium in Arizona, California, District of Columbia, Florida, Hawaii, Iowa, Massachusetts, Maine, Michigan , Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Mexico, North Carolina, North Dakota, Oregon, South Dakota, Vermont, West Virginia and Wisconsin;

(3)

Brand or generic Diovan Nationwide Class. From September 28, 2012 to April 1, 2020, you purchased or paid part or all of the purchase price of Diovan and / or generic AB-classified versions of Diovan in the United States and its territories;

(4)

Brand or generic Diovan State Law Class. From September 28, 2012 to April 1, 2020, you purchased or paid part or all of the purchase price of Diovan and / or generic AB-rated versions of Diovan in Arizona, California, District of Columbia, Florida, Hawaii, Iowa , Massachusetts, Maine, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Mexico, North Carolina, North Dakota, Oregon, South Dakota, Vermont, West Virginia and Wisconsin;

(5)

Brand or generic Valcyte National class. From August 1, 2014 to April 1, 2020, you purchased or paid part or all of the purchase price of Valcyte and / or generic AB rated versions of Valcyte in the United States and its territories; Where

(6)

Brand or generic Valcyte State Law Class. From August 1, 2014 to April 1, 2020, you purchased or paid part or all of the purchase price of Valcyte and / or generic AB rated versions of Valcyte in Arizona, California, District of Columbia, Florida, Hawaii, Iowa , Massachusetts, Maine, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Mexico, North Carolina, North Dakota, Oregon, South Dakota, Vermont, West Virginia and Wisconsin.

Excluded from the six classes: consumers who are natural persons; The defendants, their officers, directors, officers, employees, subsidiaries and affiliates; all federal and state government entities except cities, towns, municipalities or counties with self-funded drug plans; all persons or entities who purchased the drugs in issue for the purpose of resale from one of the defendants or from any brand or generic manufacturer; fully insured health plans (that is to say, health insurance plans that have purchased insurance covering 100% of their reimbursement obligation to members); and drug benefit managers.

Your rights and options

DO NOTHING: If you are a member of a group, by doing nothing you will remain in that group and may have the right to share any recoveries that may arise from a lawsuit or a settlement with the defendants for that group. You will be bound by any decision of the Court in this legal action (including a judgment in favor of the Defendants) with respect to this Class, and you will waive your rights to sue any of the Defendants over the same set of facts, series of transactions or legal claims involved in this lawsuit regarding this class.

EXCLUDE YOURSELF: This is the only option that allows you to file or be part of another legal action against the defendants regarding the claims in this case. If you exclude yourself from certain Groups, you will not be bound by any of the orders of the Court in this matter relating to the claims of those Groups against the Defendants, and you will not be entitled to participate in and benefit from any recovery, if applicable, on behalf of these Classes. Any dispute regarding your exclusion request will be resolved by the Court. If you are a class member for more than one drug, you can exclude yourself from all classes for a particular drug but choose to stay in the other classes. The deadline to exclude yourself from classes is 20 December 2021. Specific instructions on how to request the exclusion are included in the Detailed Notice available for download at www.RanbaxyTPPLitigation.com.

The trial

The trial is scheduled to begin on January 10, 2022, at the American courthouse John Joseph Moakley, One Courthouse Way, Boston, Massachusetts 02210. Any changes to the date or location of the trial will be posted on the case website.

Do you want more information?

Go to www.RanbaxyTPPLitigation.com, call 1-877-888-9232, email [email protected], or write to Ranbaxy TPP Litigation, PO Box 173137, Milwaukee, WI 53217.

Cision

View original content: https://www.prnewswire.com/news-releases/lowey-dannenberg-pc-and-the-dugan-law-firm-aplc-announce-courts-certification-of-class-action-involving – third-party-payers-payment-or-reimbursement-for-part-or-all-of-the-purchase-price-of-generic-nexium-esomeprazole-magnes-301417807.html

THE SOURCE Lowey dannenberg, PC and the Dugan law firm, APLC


Source link

Share.

About Author

Leave A Reply